The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

Slides:

Advertisements

Similar presentations

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.

Advertisements

Modulation of the intensiveness of glucose lowering in type 2 diabetes

Volume 70, Issue 8, Pages (October 2006)

Rank-order bar chart of percentage of patient-days with blood glucose results > 299 mg/dl for non-ICU units. Rank-order bar chart of percentage of patient-days.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Protocol for management of adult patients with DKA or HHS

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.

Suggested pathway for discussions between healthcare professionals and people with diabetes intending to fast during Ramadan. CBG, capillary blood glucose; DVLA,

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Trends in prevalence of diabetes in middle-aged women grouped according to BMI at the first survey of the ALSWH. ▪, healthy (n = 5,252); ♦, overweight.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Glucose, insulin, and AGE levels during an OGC before and after RT

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

An algorithm depicting the basic approach to the Charcot foot

FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Algorithm for the management of patients with prediabetes or T2DM and definite NASH. This suggested therapeutic algorithm is based on the safety and efficacy.

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.

Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

The underlying physiological basis of the HOMA model.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Scatterplot of the RR estimates of type 2 diabetes reported in the 15 included studies, and the pooled RR estimates with corresponding 95% CIs for five.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Glucose control performance (by CGM) characterized by median and interquartile range cumulative % time in glucose range (A), overall glucose (B), and insulin.

Effect of age, sex, race/ethnicity, and obesity on the relation of glycemic measures to Si and AIR. In linear regression models with Si as the dependent.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Oral glucose tolerance testing during hospitalization and at 4 months after infarction. Oral glucose tolerance testing during hospitalization and at 4 months.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Blood glucose levels in chicken embryos.

Proportion of patients experiencing documented symptomatic hypoglycemia (blood glucose

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

SDF-1, adiponectin, and sVCAM levels are higher in Medalists than controls, but SDF-1 does not differ with respect to vascular complications; PAI-1 and.

Waveform analysis at the popliteal artery in 176 diabetic patients with normal ABI (non-PAD). Waveform analysis at the popliteal artery in 176 diabetic.

A total of 173 individuals were positive for GADA, and 16 of these were positive for a second antibody (11 were IA-2A positive, and 6 were ZnT8A positive).

Meal control achieved in the five meals of the study (the first dinner was handled in open-loop mode, and all other meals were handled by closed-loop).

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Case report: male 63 years old with documented stenosis of the internal cerebral artery, diabetes duration 12 years, and treatment with 22 IU insulin glargine.

Graph showing percentage of total patients with PTD or IGT that would be detected in each category of FBG if an oral glucose tolerance test were performed.

Correlations between leptin DNA methylation and 2-h post-OGTT glucose levels, within the IGT group (A and B), leptin DNA methylation and mRNA levels (C.

Changes (means±posterior SDs) in HbA1c (A), fasting glucose (B), and body weight (C) by treatment condition based on missing not at random (MNAR) analyses.

Number of antihypertensive agents prescribed for known nephropaths in phases I and II (▪), with blood pressure recordings falling outside guidelines, compared.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

RBP4 and glucose metabolism.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Distribution of daily frequency of BGM

Plots of average estimated and measured GFR vs

Schematic representation of the control of muscle glucose uptake during exercise. Schematic representation of the control of muscle glucose uptake during.

The continuous line represents the sensor glucose values.

Incidences of transitions between glycemic states by 25-OHD level.

Postoperative blood glucose levels and total insulin requirement.

A1C at baseline, 16 weeks, and 32 weeks according to study group in all participants (A), adult participants (B), and adolescent participants (C) who returned.

WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)

The solid line represents the point estimate of the treatment ORs at various levels along the x-axis that ranges from the minimum to the maximum observed.

A: Glucose levels during basal-bolus and SSI treatment.

Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The database includes 120,618 blood glucose values in 5,808 runs. The mean blood glucose level reached <150 mg/dl in 3 h. The source of variance in blood glucose levels after the target was reached includes the effects of different targets and meter measurement variance as well as reflecting the efficacy of the algorithm. Paul C. Davidson et al. Dia Care 2005;28:2418-2423 ©2005 by American Diabetes Association